Evidence map›Paper›PMID 42096175›Full record

ReviewRevista medica del Instituto Mexicano del Seguro Social2026

[Psychiatry as clinical neuroscience].

José Luis Jiménez-López

Abstract readReviewEnglish Abstract
In one paragraph

Review in Revista medica del Instituto Mexicano del Seguro Social, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

José Luis Jiménez-LópezInstituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, Hospital de Especialidades "Dr. Antonio Fraga Mouret", Departamento de Psiquiatría y Psicología. Ciudad de México, México.ORCID 0000-0002-9653-6541

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For more than a century, psychiatry has established its clinical practice on syndrome-based descriptions grouped into exclusive diagnostic categories and on the prescription of psychotropic drugs aimed at modifying signs and symptoms, with etiological hypotheses formulated from different theoretical frameworks, ranging from psychoanalytic to neurobiological. Recent research from a neuroscientific theoretical framework suggests that different psychiatric illnesses are interconnected at different levels. The approach to mental disorders from this new perspective has generated more precise etiological hypotheses, has favored the development of initiatives that recommend a radical change in psychiatric taxonomy, and has oriented pharmacological research to other therapeutic targets. This article raises the possibility of psychiatry being positioned as a clinical neuroscience based on studies on brain connectivity as a substrate of mental functioning (Human Connectome Project), transdiagnostic nosological classification initiatives from a dimensional and spectral perspective (Research Domain Criteria and Hierarchical Taxonomy of Psychopathology) the new psychopharmacological nomenclature based on neurosciences and the findings in genomic association studies. The paradigm shift for the approach to mental disorders also includes the training of specialists in psychiatry, which is why the inclusion of neuroscience subjects in medical residency programs is recommended.

Indexed as

Mental DisordersNeurosciencesPsychiatryHumansConectomaConnectomeMental DisordersNeurobiologíaNeurobiologyNeurocienciasNeurosciencesTrastornos Mentales

Identifiers

PMID42096175
PMCPMC13193626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.